Septerna Stock

$11.99

2.48% day before yesterday

Nasdaq, Aug 22, 10:00 pm CET

ISIN

US81734D1046

Symbol

SEPN

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Septerna Stock price

$11.99

-6.01 33.39% 5Y

Nasdaq, Closing price Fri, Aug 22 2025

+0.29 2.48%

ISIN

US81734D1046

Symbol

SEPN

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$534.6m

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

negative | 13.9

P/S

732.3 | 7.5

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

92.0%

Return on Equity

-17.1%

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$730.0k | $71.3m

EBITDA

$-100.6m | $-65.3m

EBIT

$-102.2m | $-10.9m

Net Income

$-87.5m | -

Free Cash Flow

$-83.0m

EPS

$-2.0

FCF per Share

Short interest

12.4%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Get Started for Free Today

Septerna Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Septerna forecast:

9x Buy

82%

2x Hold

18%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Septerna forecast:

Buy

82%

Hold

18%

Analyst Estimates with Stock Price Targets

Financial data from Septerna

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	0.73 0.73	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	24 24	- 3,325%
- Research and Development Expense	79 79	- 10,768%
EBITDA	-101 -101	- -13,781%
- Depreciation and Amortization	1.55 1.55	- 212%
EBIT (Operating Income) EBIT	-102 -102	- -13,994%
Net Profit	-88 -88	- -11,988%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Septerna Stock News

Neutral

GlobeNewsWire

●

3 days ago

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative al...

Neutral

GlobeNewsWire

●

12 days ago

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of ...

Neutral

GlobeNewsWire

●

3 months ago

Septerna to Present at Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D.

More Septerna News

Company Profile

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Head office	United States
CEO	Jeffrey Finer
Website	septerna.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now